Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) — SEGNO

Oligometastatic Prostate Cancer Clinical Trial

Official title:
An Exploratory Study of the Safety and Efficacy of Genomic Biomarker-guided Neoadjuvant Therapy for Locally Advanced and Oligometastatic Prostate Cancer (SEGNO)

Status Recruiting

Clinical Trial Summary

To evaluated the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer.

Clinical Trial Description

According to the results of the genomic profile, patients will be assigned to 4 neoadjuvant therapy (NT) groups (Queue 1 to 4): Queue 1: No targetable actionable aberration; Queue 2: Homologous recombination repair (HRR) alterations (BRCA1/2); Queue 3: Homologous recombination repair alterations (except BRCA1/2 and CDK12); Queue 4: MSI-H/dMMR, TMB≥10mut/Mb or CDK12 alterations without other HRR alterations. A following PSMA PETCT for evaluating the efficacy of NT and radical prostatectomy (RP) plus pelvic lymph node dissection (PLND) will be perform. The histopathological and survival data after RP plus PLND will also be evaluated. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06387056
Study type	Interventional
Source	The First Affiliated Hospital of Xiamen University
Contact	Kaiyan Zhang, M.D.
Phone	+865922139714
Email	zkyken@163.com
Status	Recruiting
Phase	Phase 2
Start date	April 1, 2024
Completion date	April 1, 2029

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03940235` - Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis	Phase 2
Completed	`NCT01859221` - Radiotherapy for Oligometastatic Prostate Cancer	N/A
Recruiting	`NCT06060652` - Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)
Recruiting	`NCT04610372` - 5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)	N/A
Recruiting	`NCT05915442` - Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer	Phase 2
Active, not recruiting	`NCT04992026` - The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer	Phase 2
Recruiting	`NCT05560659` - Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy	Phase 2
Completed	`NCT02192788` - Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer	N/A